MURRAY HILL, N.J.--(BUSINESS WIRE)-- C. R. Bard, Inc. (NYS: BCR) today announced that it has entered into a definitive agreement to acquire privately-held Neomend, Inc., a leading developer and ...
Renowned medical devices maker CR Bard (BCR) recently announced a definitive agreement to purchase leading thoracic sealing company Neomend Inc. for $140 million in cash and will pay contingent ...
C.R. Bard ($BCR) has agreed to pay $140 million up-front for Neomend, a California maker of products to seal air leaks in the lungs after surgery. The deal is ...
C. R. Bard announced that it has entered into a definitive agreement to acquire privately-held Neomend, a leading developer and supplier of sprayable surgical sealants and anti-adhesion products for a ...
C.R. Bard, the Murray Hill, N.J., publicly traded medical device company, has acquired Neomend in a $140 million deal. Neomend, Irvine, Calif., which develops sprayable surgical sealants and ...
Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received the European Union CE Mark for the company's ProGEL® PLATINUM Surgical ...
Novozymes Biopharma, has announced that its recombinant human albumin, albucult®, is being used by Neomend in its ProGEL® PLATINUM surgical sealant. This product will be commercially available in ...
Renowned medical devices maker CR Bard (BCR) recently announced a definitive agreement to purchase leading thoracic sealing company Neomend Inc. for $140 million in cash and will pay contingent ...
Renowned medical devices maker CR Bard ( BCR) recently announced a definitive agreement to purchase leading thoracic sealing company Neomend Inc. for $140 million in cash and will pay contingent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results